Axsome Therapeutics announces completion of patient enrollment in the GEMINI phase 3 trial
Axsome Therapeutics announced completion of patient enrollment in the GEMINI study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in patients with major depressive disorder. Axsome remains on track to report topline results from GEMINI in the fourth quarter of 2019. October 16, 2019